+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Patient-Derived Xenograft/PDX Model Market Research Report by Type (Mice Models and Rat Models), End User, Tumor Type, Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 230 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 5637019
UP TO OFF until Dec 31st 2022
The Global Patient-Derived Xenograft/PDX Model Market size was estimated at USD 171.22 million in 2021, USD 194.97 million in 2022, and is projected to grow at a CAGR 14.12% to reach USD 378.32 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Patient-Derived Xenograft/PDX Model to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market was studied across Mice Models and Rat Models.
  • Based on End User, the market was studied across Academic & Research Institutions, Contract Research Organizations (CROs), and Pharmaceutical & Biotechnology Companies.
  • Based on Tumor Type, the market was studied across Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models, Other Tumor Models, Respiratory Tumor Models, and Urological Tumor Models.
  • Based on Application, the market was studied across Basic Cancer Research, Biomarker Analysis, and Preclinical Drug Development.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Patient-Derived Xenograft/PDX Model market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Patient-Derived Xenograft/PDX Model Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Patient-Derived Xenograft/PDX Model Market, including Abnova Corporation, Champions Oncology, Inc., Charles River Laboratories, Envigo, EPO Berlin-Buch GmbH, Explora BioLabs, Genesis Biotechnology Group, Hera BioLabs, Oncodesign, Pharmatest Services, SR Corporation, THE JACKSON LABORATORY, Urosphere, WuXi AppTec, and Xentech.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Patient-Derived Xenograft/PDX Model Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Patient-Derived Xenograft/PDX Model Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Patient-Derived Xenograft/PDX Model Market?
4. What is the competitive strategic window for opportunities in the Global Patient-Derived Xenograft/PDX Model Market?
5. What are the technology trends and regulatory frameworks in the Global Patient-Derived Xenograft/PDX Model Market?
6. What is the market share of the leading vendors in the Global Patient-Derived Xenograft/PDX Model Market?
7. What modes and strategic moves are considered suitable for entering the Global Patient-Derived Xenograft/PDX Model Market?
Frequently Asked Questions about the Global Patient-Derived Xenograft/PDX Model Market

What is the estimated value of the Global Patient-Derived Xenograft/PDX Model Market?

The Global Patient-Derived Xenograft/PDX Model Market was estimated to be valued at $171.22 Million in 2021.

What is the growth rate of the Global Patient-Derived Xenograft/PDX Model Market?

The growth rate of the Global Patient-Derived Xenograft/PDX Model Market is 14.1%, with an estimated value of $378.32 Million by 2027.

What is the forecasted size of the Global Patient-Derived Xenograft/PDX Model Market?

The Global Patient-Derived Xenograft/PDX Model Market is estimated to be worth $378.32 Million by 2027.

Who are the key companies in the Global Patient-Derived Xenograft/PDX Model Market?

Key companies in the Global Patient-Derived Xenograft/PDX Model Market include Abnova Corporation, Champions Oncology, Inc., Charles River Laboratories, Envigo, EPO Berlin, Buch GmbH, Explora BioLabs, Genesis Biotechnology Group and Oncodesign.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing Demand for Personalized Medicine
5.1.1.2. Oncology and Preclinical Development
5.1.1.3. Government Programs Funding and Services for Applicants in the Preparation of Their Preclinical Programs and Documentation
5.1.2. Restraints
5.1.2.1. High Cost of Personalized Pdx Model
5.1.3. Opportunities
5.1.3.1. Rising Demand for Humanized Pdx Model
5.1.3.2. Growth in Pharma R&D
5.1.4. Challenges
5.1.4.1. Stringent Guidelines Regarding the Ethical Use of Animals in Cancer Research
5.2. Cumulative Impact of COVID-19
6. Patient-Derived Xenograft/Pdx Model Market, by Type
6.1. Introduction
6.2. Mice Models
6.3. Rat Models
7. Patient-Derived Xenograft/Pdx Model Market, by End-user
7.1. Introduction
7.2. Academic & Research Institutions
7.3. Contract Research Organizations (Cros)
7.4. Pharmaceutical & Biotechnology Companies
8. Patient-Derived Xenograft/Pdx Model Market, by Tumor Type
8.1. Introduction
8.2. Gastrointestinal Tumor Models
8.3. Gynecological Tumor Models
8.4. Hematological Tumor Models
8.5. Other Tumor Models
8.6. Respiratory Tumor Models
8.7. Urological Tumor Models
9. Patient-Derived Xenograft/Pdx Model Market, by Application
9.1. Introduction
9.2. Basic Cancer Research
9.3. Biomarker Analysis
9.4. Preclinical Drug Development
10. Americas Patient-Derived Xenograft/Pdx Model Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Patient-Derived Xenograft/Pdx Model Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
12. Europe, Middle East & Africa Patient-Derived Xenograft/Pdx Model Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom
13. Competitive Landscape
13.1. Fpnv Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, by Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abnova Corporation
14.2. Champions Oncology, Inc.
14.3. Charles River Laboratories
14.4. Envigo
14.5. Epo Berlin-Buch GmbH
14.6. Explora Biolabs
14.7. Genesis Biotechnology Group
14.8. Hera Biolabs
14.9. Oncodesign
14.10. Pharmatest Services
14.11. Sr Corporation
14.12. the Jackson Laboratory
14.13. Urosphere
14.14. Wuxi Apptec
14.15. Xentech
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2027
FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2021 VS 2027 (%)
FIGURE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2021 VS 2027 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2027
FIGURE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2019-2027 (USD MILLION)
FIGURE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), 2019-2027 (USD MILLION)
FIGURE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2019-2027 (USD MILLION)
FIGURE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2021 VS 2027 (%)
FIGURE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 26. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2027
FIGURE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, 2019-2027 (USD MILLION)
FIGURE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, 2019-2027 (USD MILLION)
FIGURE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, 2019-2027 (USD MILLION)
FIGURE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY OTHER TUMOR MODELS, 2019-2027 (USD MILLION)
FIGURE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY OTHER TUMOR MODELS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 35. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, 2019-2027 (USD MILLION)
FIGURE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 37. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, 2019-2027 (USD MILLION)
FIGURE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 39. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 40. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 41. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2027
FIGURE 42. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, 2019-2027 (USD MILLION)
FIGURE 43. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 44. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, 2019-2027 (USD MILLION)
FIGURE 45. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 46. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, 2019-2027 (USD MILLION)
FIGURE 47. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 48. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 50. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2027
FIGURE 52. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 53. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 55. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 56. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 57. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 58. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 59. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2027
FIGURE 60. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 61. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 62. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 63. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2027
FIGURE 64. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 67. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 68. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 69. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 70. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 71. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 72. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 73. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 74. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 75. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 76. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 77. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 78. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2027
FIGURE 79. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 80. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 81. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 82. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 83. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 84. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 85. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 86. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 87. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 88. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 89. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 90. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 91. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 92. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2019-2027 (USD MILLION)
TABLE 7. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2019-2027 (USD MILLION)
TABLE 12. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2019-2027 (USD MILLION)
TABLE 18. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 19. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY STATE, 2019-2027 (USD MILLION)
TABLE 20. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2019-2027 (USD MILLION)
TABLE 23. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY STATE, 2019-2027 (USD MILLION)
TABLE 25. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019-2027 (USD MILLION)
TABLE 28. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 30. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 31. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2019-2027 (USD MILLION)
TABLE 34. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY STATE, 2019-2027 (USD MILLION)
TABLE 36. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2019-2027 (USD MILLION)
TABLE 39. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 40. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY STATE, 2019-2027 (USD MILLION)
TABLE 41. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 42. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 43. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2019-2027 (USD MILLION)
TABLE 44. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 45. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY STATE, 2019-2027 (USD MILLION)
TABLE 46. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 47. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 48. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY OTHER TUMOR MODELS, BY REGION, 2019-2027 (USD MILLION)
TABLE 49. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY OTHER TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 50. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY OTHER TUMOR MODELS, BY STATE, 2019-2027 (USD MILLION)
TABLE 51. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY OTHER TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY OTHER TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 53. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2019-2027 (USD MILLION)
TABLE 54. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 55. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY STATE, 2019-2027 (USD MILLION)
TABLE 56. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 58. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2019-2027 (USD MILLION)
TABLE 59. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 60. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY STATE, 2019-2027 (USD MILLION)
TABLE 61. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 63. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 64. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2019-2027 (USD MILLION)
TABLE 65. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 66. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY STATE, 2019-2027 (USD MILLION)
TABLE 67. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 69. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 70. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 71. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 72. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 74. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2019-2027 (USD MILLION)
TABLE 75. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 76. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY STATE, 2019-2027 (USD MILLION)
TABLE 77. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 79. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 80. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 81. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 82. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 83. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 84. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 85. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 86. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 87. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 88. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 89. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 90. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 91. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 92. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 93. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 94. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 95. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 96. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 97. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 98. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 99. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 100. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 101. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 102. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 103. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 104. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 105. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 106. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 107. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 108. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 109. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 110. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 111. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 112. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 113. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 114. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 115. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 116. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 117. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 118. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 119. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 120. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 121. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 122. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 123. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 124. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 125. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 126. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 127. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 128. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 129. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 130. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 131. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 132. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 133. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 134. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 135. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 136. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 137. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 138. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 139. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 140. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 141. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 142. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 143. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 144. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 145. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 146. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 147. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 148. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 149. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 150. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 151. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 152. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 153. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 154. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 155. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 156. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 157. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 158. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 159. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 160. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 161. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 162. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 163. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 164. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 165. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 166. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 167. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 168. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 169. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 170. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 171. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 178. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 179. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 180. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 181. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 182. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 183. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 184. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 185. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 186. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 187. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 188. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 189. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 190. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 191. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 192. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 193. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 194. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 195. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 196. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 197. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 198. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 199. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 200. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 201. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 202. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 203. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 204. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 205. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 206. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 207. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 208. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 209. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 210. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 211. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 212. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 213. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 214. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 215. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 216. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 217. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 218. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 219. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 220. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 221. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 222. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 228. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 229. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 230. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 231. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2019-2027 (USD MILLION)
TABLE 232. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2019-2027 (USD MILLION)
TABLE 233. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 234. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 235. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 236. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RANKING
TABLE 237. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2021
TABLE 238. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET MERGER & ACQUISITION
TABLE 239. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 240. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 241. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET INVESTMENT & FUNDING
TABLE 242. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 243. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET: LICENSE & PRICING

Companies Mentioned

  • Abnova Corporation
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Envigo
  • EPO Berlin-Buch GmbH
  • Explora BioLabs
  • Genesis Biotechnology Group
  • Hera BioLabs
  • Oncodesign
  • Pharmatest Services
  • SR Corporation
  • THE JACKSON LABORATORY
  • Urosphere
  • WuXi AppTec
  • Xentech

Methodology

Loading
LOADING...